Source: Medicines and Medical Devices Safety Authority (NZ) Revision Year: 2018 Publisher: Pharmacy Retailing (NZ) Ltd t/a Healthcare Logistics, 58 Richard Pearse Drive, Airport Oaks, Mangere, AUCKLAND Telephone: (09) 918 5100 Fax: (09) 918 5101
ISMO 40 retard tablets.
| Pharmaceutical Form |
|---|
|
ISMO 40 retard prolonged-release tablets for oral administration are white, round, coated tablets with a diameter of 6.5–7.0 mm and a thickness of 3.3–3.8 mm. |
Each prolonged-release tablet contains 40 mg isosorbide mononitrate.
Contains glucose syrup, lactose and sucrose.
For a full list of excipients, see section 6.1.
| Active Ingredient | Description | |
|---|---|---|
| Isosorbide mononitrate |
Isosorbide mononitrate is an organic nitrate, which, in common with other cardioactive nitrates, is a vasodilator. It produces decreased left and right ventricular end-diastolic pressures to a greater extent than the decrease in systemic arterial pressure, thereby reducing afterload and especially the preload of the heart. |
| List of Excipients |
|---|
|
Glucose syrup |
ISMO 40 retard is supplied in blister packs of 30 tablets.
Pharmacy Retailing (NZ) Ltd t/a Healthcare Logistics, 58 Richard Pearse Drive, Airport Oaks, Mangere, AUCKLAND
Telephone: (09) 918 5100
Fax: (09) 918 5101
Date of first approval: 2 December 2010
| Drug | Countries | |
|---|---|---|
| ISMO | Germany, Italy, New Zealand, United Kingdom, South Africa |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
